PUBLISHER: Persistence Market Research | PRODUCT CODE: 1767752
PUBLISHER: Persistence Market Research | PRODUCT CODE: 1767752
Infectious Disease In-vitro Diagnostics Market by Product Type, End-Users, and Geography: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
Persistence Market Research has recently released a comprehensive report on the worldwide market for infectious disease in-vitro diagnostics (IVD). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global infectious disease IVD market from 2025 to 2032.
Key Insights:
- Infectious Disease IVD Market Size (2025E): USD 46.6 Billion
- Projected Market Value (2032F): USD 64.1 Billion
- Global Market Growth Rate (CAGR 2025 to 2032): 4.7%
Infectious Disease In-vitro Diagnostics Market - Report Scope:
Infectious disease in-vitro diagnostics play a crucial role in the rapid and accurate detection of pathogens responsible for infections such as HIV, hepatitis, influenza, tuberculosis, and emerging viral threats like SARS-CoV-2. These diagnostics encompass molecular assays, immunoassays, and point-of-care testing technologies, enabling early diagnosis, guiding treatment decisions, and facilitating infection control efforts. The infectious disease IVD market caters to hospitals, clinical laboratories, diagnostic centers, and point-of-care settings, offering a diverse array of test kits, reagents, instruments, and software solutions. Market growth is driven by the rising prevalence of infectious diseases, increased demand for rapid and accurate testing, and technological advancements in diagnostic platforms, improving sensitivity, specificity, and turnaround times.
Market Growth Drivers:
The global infectious disease IVD market is propelled by several key factors, including the growing incidence of infectious diseases worldwide and heightened awareness of early detection and disease management. The increasing burden of antibiotic-resistant infections, the need for precise diagnostics in outbreak scenarios, and robust government initiatives supporting infectious disease surveillance and screening further accelerate market growth. Technological progress in molecular diagnostics, such as next-generation sequencing and multiplex PCR, enables simultaneous detection of multiple pathogens, enhancing clinical decision-making and patient outcomes. Moreover, the expanding use of point-of-care tests for infectious disease screening in decentralized healthcare settings contributes significantly to market expansion, offering convenience and faster diagnosis, especially in resource-limited regions.
Market Restraints:
Despite promising growth prospects, the infectious disease IVD market faces challenges related to stringent regulatory frameworks, complex approval processes, and reimbursement limitations in certain regions. Variations in regulatory requirements across countries create barriers for global market penetration and increase development timelines and costs for manufacturers. Additionally, the high cost of advanced molecular diagnostic systems and tests can restrict adoption, particularly in low- and middle-income countries where budget constraints affect healthcare spending. Moreover, concerns around test accuracy, false-positive or false-negative results, and quality control in decentralized settings pose ongoing challenges for market players striving to maintain diagnostic reliability and clinical trust.
Market Opportunities:
The infectious disease IVD market presents significant growth opportunities driven by technological innovations, global health priorities, and evolving diagnostic needs. The integration of digital health tools, such as cloud-based data management and artificial intelligence-driven diagnostic algorithms, improves diagnostic accuracy, enables remote analysis, and supports disease surveillance and outbreak tracking. Furthermore, rising investment in research and development for novel biomarkers, rapid diagnostic tests, and syndromic testing panels expands the market scope and addresses unmet clinical needs. The shift toward personalized medicine, increased public-private collaborations, and growing emphasis on preparedness for emerging infectious diseases create avenues for market players to develop innovative solutions and strengthen market presence in the dynamic infectious disease diagnostics landscape.
Key Questions Answered in the Report:
- What are the primary factors driving the growth of the infectious disease IVD market globally?
- Which test types and applications are driving the adoption of infectious disease diagnostics across various healthcare settings?
- How are technological advancements reshaping the competitive landscape of the infectious disease IVD market?
- Who are the key players contributing to the infectious disease IVD market, and what strategies are they employing to maintain market relevance?
- What are the emerging trends and future prospects in the global infectious disease IVD market?
Competitive Intelligence and Business Strategy:
These companies invest in R&D to develop high-sensitivity molecular assays, multiplexed platforms, and rapid point-of-care diagnostics, addressing diverse infectious disease testing needs. Partnerships with healthcare providers, governments, and international health organizations facilitate access to markets, especially during public health emergencies. Moreover, emphasis on automation, integration of digital solutions, and adherence to regulatory standards enables market leaders to deliver reliable, scalable, and cost-effective diagnostic solutions. Continuous efforts in clinical research, assay validation, and global distribution networks further consolidate the competitive landscape in the rapidly evolving infectious disease IVD market.
Key Companies Profiled:
- QIAGEN
- Becton, Dickinson and Company
- bioMerieux SA
- F. Hoffmann-La Roche, Ltd.
- Hologic, Inc. (Gen Probe)
- Abbott
- Quidel Corporation
- Siemens Healthineers AG
- Bio-Rad Laboratories, Inc.
- Danaher
- OraSure Technologies, Inc.
Infectious Disease IVD Market Research Segmentation:
The infectious disease IVD market encompasses a diverse range of products, technologies, applications, and end-user segments, addressing various pathogens and patient populations.
By Product Type
- Instruments
- Reagents
- Software and Services
By Technology
- Immunoassay
- Molecular Diagnostics
- Microbiology
- Others
By Application
- MRSA
- Clostridium Difficile
- Respiratory Virus
- TB and Drug-resistant TB
- Gonorrhea
- HPV
- HIV
- Hepatitis C
- Hepatitis B
- COVID-19
- Others
By End User
- Point-of-care
- Central Laboratories
- Others
By Region
- North America
- Europe
- East Asia
- South Asia and Oceania
- Latin America
- Middle East and Africa
Table of Contents
1. Executive Summary
- 1.1. Global Infectious Disease In-vitro Diagnostics Market Snapshot, 2025 and 2032
- 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
- 1.3. Key Market Trends
- 1.4. Future Market Projections
- 1.5. Premium Market Insights
- 1.6. Industry Developments and Key Market Events
- 1.7. PMR Analysis and Recommendations
2. Market Overview
- 2.1. Market Scope and Definition
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
- 2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.4. COVID-19 Impact Analysis
- 2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
- 3.1. Regulatory Landscape
- 3.2. Product Adoption Analysis
- 3.3. Value Chain Analysis
- 3.4. Key Deals and Mergers
- 3.5. PESTLE Analysis
- 3.6. Porter's Five Force Analysis
4. Global Infectious Disease In-vitro Diagnostics Market Outlook:
- 4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
- 4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
- 4.3. Global Infectious Disease In-vitro Diagnostics Market Outlook: Product Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019-2024
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 4.3.3.1. Instruments
- 4.3.3.2. Reagents
- 4.3.3.3. Software and Services
- 4.3.4. Market Attractiveness Analysis: Product Type
- 4.4. Global Infectious Disease In-vitro Diagnostics Market Outlook: Technology
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
- 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 4.4.3.1. Immunoassay
- 4.4.3.2. Molecular Diagnostics
- 4.4.3.3. Microbiology
- 4.4.3.4. Others
- 4.4.4. Market Attractiveness Analysis: Technology
- 4.5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Application
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 4.5.3.1. MRSA
- 4.5.3.2. Clostridium Difficile
- 4.5.3.3. Respiratory Virus
- 4.5.3.4. TB and Drug-resistant TB
- 4.5.3.5. Gonorrhea
- 4.5.3.6. HPV
- 4.5.3.7. HIV
- 4.5.3.8. Hepatitis C
- 4.5.3.9. Hepatitis B
- 4.5.3.10. COVID-19
- 4.5.3.11. Others
- 4.5.4. Market Attractiveness Analysis: Application
- 4.6. Global Infectious Disease In-vitro Diagnostics Market Outlook: End User
- 4.6.1. Introduction / Key Findings
- 4.6.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
- 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 4.6.3.1. Point-of-care
- 4.6.3.2. Central Laboratories
- 4.6.3.3. Others
- 4.6.4. Market Attractiveness Analysis: End User
5. Global Infectious Disease In-vitro Diagnostics Market Outlook: Region
- 5.1. Key Highlights
- 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
- 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
- 5.4. Market Attractiveness Analysis: Region
6. North America Infectious Disease In-vitro Diagnostics Market Outlook:
- 6.1. Key Highlights
- 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 6.2.1. By Country
- 6.2.2. By Product Type
- 6.2.3. By Technology
- 6.2.4. By Application
- 6.2.5. By End User
- 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 6.3.1. U.S.
- 6.3.2. Canada
- 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 6.4.1. Instruments
- 6.4.2. Reagents
- 6.4.3. Software and Services
- 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 6.5.1. Immunoassay
- 6.5.2. Molecular Diagnostics
- 6.5.3. Microbiology
- 6.5.4. Others
- 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 6.6.1. MRSA
- 6.6.2. Clostridium Difficile
- 6.6.3. Respiratory Virus
- 6.6.4. TB and Drug-resistant TB
- 6.6.5. Gonorrhea
- 6.6.6. HPV
- 6.6.7. HIV
- 6.6.8. Hepatitis C
- 6.6.9. Hepatitis B
- 6.6.10. COVID-19
- 6.6.11. Others
- 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 6.7.1. Point-of-care
- 6.7.2. Central Laboratories
- 6.7.3. Others
- 6.8. Market Attractiveness Analysis
7. Europe Infectious Disease In-vitro Diagnostics Market Outlook:
- 7.1. Key Highlights
- 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Product Type
- 7.2.3. By Technology
- 7.2.4. By Application
- 7.2.5. By End User
- 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Rest of Europe
- 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 7.4.1. Instruments
- 7.4.2. Reagents
- 7.4.3. Software and Services
- 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 7.5.1. Immunoassay
- 7.5.2. Molecular Diagnostics
- 7.5.3. Microbiology
- 7.5.4. Others
- 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 7.6.1. MRSA
- 7.6.2. Clostridium Difficile
- 7.6.3. Respiratory Virus
- 7.6.4. TB and Drug-resistant TB
- 7.6.5. Gonorrhea
- 7.6.6. HPV
- 7.6.7. HIV
- 7.6.8. Hepatitis C
- 7.6.9. Hepatitis B
- 7.6.10. COVID-19
- 7.6.11. Others
- 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 7.7.1. Point-of-care
- 7.7.2. Central Laboratories
- 7.7.3. Others
- 7.8. Market Attractiveness Analysis
8. East Asia Infectious Disease In-vitro Diagnostics Market Outlook:
- 8.1. Key Highlights
- 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Product Type
- 8.2.3. By Technology
- 8.2.4. By Application
- 8.2.5. By End User
- 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 8.4.1. Instruments
- 8.4.2. Reagents
- 8.4.3. Software and Services
- 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 8.5.1. Immunoassay
- 8.5.2. Molecular Diagnostics
- 8.5.3. Microbiology
- 8.5.4. Others
- 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 8.6.1. MRSA
- 8.6.2. Clostridium Difficile
- 8.6.3. Respiratory Virus
- 8.6.4. TB and Drug-resistant TB
- 8.6.5. Gonorrhea
- 8.6.6. HPV
- 8.6.7. HIV
- 8.6.8. Hepatitis C
- 8.6.9. Hepatitis B
- 8.6.10. COVID-19
- 8.6.11. Others
- 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 8.7.1. Point-of-care
- 8.7.2. Central Laboratories
- 8.7.3. Others
- 8.8. Market Attractiveness Analysis
9. South Asia & Oceania Infectious Disease In-vitro Diagnostics Market Outlook:
- 9.1. Key Highlights
- 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Product Type
- 9.2.3. By Technology
- 9.2.4. By Application
- 9.2.5. By End User
- 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
- 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 9.4.1. Instruments
- 9.4.2. Reagents
- 9.4.3. Software and Services
- 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 9.5.1. Immunoassay
- 9.5.2. Molecular Diagnostics
- 9.5.3. Microbiology
- 9.5.4. Others
- 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 9.6.1. MRSA
- 9.6.2. Clostridium Difficile
- 9.6.3. Respiratory Virus
- 9.6.4. TB and Drug-resistant TB
- 9.6.5. Gonorrhea
- 9.6.6. HPV
- 9.6.7. HIV
- 9.6.8. Hepatitis C
- 9.6.9. Hepatitis B
- 9.6.10. COVID-19
- 9.6.11. Others
- 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 9.7.1. Point-of-care
- 9.7.2. Central Laboratories
- 9.7.3. Others
- 9.8. Market Attractiveness Analysis
10. Latin America Infectious Disease In-vitro Diagnostics Market Outlook:
- 10.1. Key Highlights
- 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Product Type
- 10.2.3. By Technology
- 10.2.4. By Application
- 10.2.5. By End User
- 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
- 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 10.4.1. Instruments
- 10.4.2. Reagents
- 10.4.3. Software and Services
- 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 10.5.1. Immunoassay
- 10.5.2. Molecular Diagnostics
- 10.5.3. Microbiology
- 10.5.4. Others
- 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 10.6.1. MRSA
- 10.6.2. Clostridium Difficile
- 10.6.3. Respiratory Virus
- 10.6.4. TB and Drug-resistant TB
- 10.6.5. Gonorrhea
- 10.6.6. HPV
- 10.6.7. HIV
- 10.6.8. Hepatitis C
- 10.6.9. Hepatitis B
- 10.6.10. COVID-19
- 10.6.11. Others
- 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 10.7.1. Point-of-care
- 10.7.2. Central Laboratories
- 10.7.3. Others
- 10.8. Market Attractiveness Analysis
11. Middle East & Africa Infectious Disease In-vitro Diagnostics Market Outlook:
- 11.1. Key Highlights
- 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Product Type
- 11.2.3. By Technology
- 11.2.4. By Application
- 11.2.5. By End User
- 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
- 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2025-2032
- 11.4.1. Instruments
- 11.4.2. Reagents
- 11.4.3. Software and Services
- 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
- 11.5.1. Immunoassay
- 11.5.2. Molecular Diagnostics
- 11.5.3. Microbiology
- 11.5.4. Others
- 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
- 11.6.1. MRSA
- 11.6.2. Clostridium Difficile
- 11.6.3. Respiratory Virus
- 11.6.4. TB and Drug-resistant TB
- 11.6.5. Gonorrhea
- 11.6.6. HPV
- 11.6.7. HIV
- 11.6.8. Hepatitis C
- 11.6.9. Hepatitis B
- 11.6.10. COVID-19
- 11.6.11. Others
- 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
- 11.7.1. Point-of-care
- 11.7.2. Central Laboratories
- 11.7.3. Others
- 11.8. Market Attractiveness Analysis
12. Competition Landscape
- 12.1. Market Share Analysis, 2025
- 12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
- 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. QIAGEN
- 12.3.1.1. Overview
- 12.3.1.2. Segments and Products
- 12.3.1.3. Key Financials
- 12.3.1.4. Market Developments
- 12.3.1.5. Market Strategy
- 12.3.2. Becton, Dickinson and Company
- 12.3.3. bioMerieux SA
- 12.3.4. F. Hoffmann-La Roche, Ltd.
- 12.3.5. Hologic, Inc. (Gen Probe)
- 12.3.6. Abbott
- 12.3.7. Quidel Corporation
- 12.3.8. Siemens Healthineers AG
- 12.3.9. Bio-Rad Laboratories, Inc.
- 12.3.10. Danaher
- 12.3.11. OraSure Technologies, Inc.
- 12.3.12. Others
- 12.3.1. QIAGEN
13. Appendix
- 13.1. Research Methodology
- 13.2. Research Assumptions
- 13.3. Acronyms and Abbreviations
